IL-5 Antagonists (IgG1 kappa)

Description

Fasenra (benralizumab) Nucala (mepolizumab)

Background
Fasenra and Nucala are used with other asthma medications for the maintenance treatment of asthma in patients with an eosinophilic phenotype. Fasenra and Nucala are approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Fasenra and Nucala reduce severe asthma attacks by reducing the levels of blood eosinophils- a type of white blood cell that contributes to the development of asthma. Nucala is also used in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) (1-2).

Regulatory Status
FDA-approved indication:
Fasenra is interleukin-5 antagonist monoclonal antibodies (IgG1 kappa) indicated for add-on maintenance treatment of patients with severe asthma ages 12 years and older, and with an eosinophilic phenotype (2).

Nucala is an interleukin-5 antagonist monoclonal antibody (IgG1 kappa) indicated for: (1)
1. Add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype
2. The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)

Limitations of use: (1-2)
Fasenra is not indicated for treatment of other eosinophilic conditions

Fasenra and Nucala are not indicated for the relief of acute bronchospasm or status asthmaticus

Subjects enrolled in Nucala trial were required to have at least 1 of the following criteria: blood eosinophil count greater than or equal to 300 cells/mcL in past 12 months, eosinophil count greater than or equal 150 cells/ mcL in the past 90 days or sputum eosinophil count greater than or equal to 3% (1).

In clinical trials herpes zoster have occurred in some patients receiving Fasenra or Nucala and varicella vaccination should be considered if medically appropriate prior to starting therapy (1-2).

Eosinophilic granulomatosis with polyangiitis (EGPA), which was previously called the Churg-Strauss syndrome (CSS) or allergic granulomatosis and angiitis, is a multisystem disorder characterized by allergic rhinitis, asthma, and prominent peripheral blood eosinophilia. Peripheral blood eosinophilia (usually 5000 to 9000 eosinophils/microL) is the most characteristic finding, although levels over 1500 cells/microL (or greater than 10 percent of the total leukocyte count) should prompt suspicion for EGPA. The primary therapy EGPA is systemic glucocorticoids. An additional immunosuppressive agent is typically added in patients with more advanced or refractory disease (3).

The safety and efficacy of Fasenra in pediatric patients less than 12 years of age have not been established. The safety and efficacy of Nucala in pediatric patients with severe asthma younger than 6 years of age have not been established. The safety and efficacy in pediatric patients less than 18 years of age with EGPA have not been established (1-2).

Related policies
Cinqair, Dupixent, Xolair

Policy
This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Fasenra and Nucala may be considered medically necessary as add-on maintenance treatment for patients with severe asthma with an eosinophilic phenotype and if the conditions indicated below are met.
Nucala may be considered **medically necessary** in patients 18 years of age and older for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) and if the conditions below are met.

Fasenra and Nucala are considered **investigational** for all other indications.

## Prior-Approval Requirements

### Diagnoses

Patient must have **ONE** of the following **AND** submission of medical records (e.g. chart notes, laboratory values) documenting the following:

**Fasenra and Nucala**

1. Severe asthma with an eosinophilic phenotype
   a. **Fasenra only**: 12 years of age or older
   b. **Nucala only**: 6 years of age or older
      i. **Age 6-11 only**: Prescriber will be dosing the patient within the FDA labeled maintenance dose of 40 mg subcutaneously every 4 weeks
   c. Inadequate control of asthma symptoms after a minimum of 3 months of compliant use with greater than or equal to 50% adherence with **ONE** of the following within the past 6 months:
      i. Inhaled corticosteroids & long acting beta\textsubscript{2} agonist
      ii. Inhaled corticosteroids & long acting muscarinic antagonist

   **AND ONE** of the following:
   a. Eosinophil count greater than or equal 150 cells/\text{mcL} in the past 90 days
   b. Eosinophil count greater than or equal 300 cells/\text{mcL} in the past 12 months

   **Nucala only**

2. Eosinophilic granulomatosis with polyangiitis (EGPA)
   a. 18 years of age or older
   b. Inadequate treatment response, intolerance, or contraindication to **TWO** of the following medications:
i. Systemic glucocorticoids
ii. Cyclophosphamide
iii. Azathioprine
iv. Methotrexate
v. Leflunomide

AND ONE of the following:
   a. Eosinophil count greater than 1000 cells/ mcL
   b. Eosinophil count greater than 10% of the total leukocyte count

AND ALL of the following for BOTH indications:
1. NOT used for the relief of acute bronchospasm or status asthmaticus
2. NO dual therapy with another monoclonal antibody for the treatment of asthma
3. Prescriber will assess the medical appropriateness for a varicella vaccination prior to therapy

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

**Prior – Approval Renewal Requirements**

**Diagnoses**

Patient must have **ONE** of the following **AND** submission of medical records (e.g. chart notes, laboratory values) documenting the following:

**Fasenra and Nucala**

1. Severe asthma with an eosinophilic phenotype
   a. **Fasenra only**: 12 years of age or older
   b. **Nucala only**: 6 years of age or older
      i. **Age 6-11 only**: Prescriber will be dosing the patient within the FDA labeled maintenance dose of 40 mg subcutaneously every 4 weeks
   c. Decreased exacerbations and improvement in symptoms
   d. Decreased utilization of rescue medications
   e. Patient has been compliant on Fasenra/Nucala therapy
Nucala Only

2. Eosinophilic granulomatosis with polyangiitis (EGPA)
   
   a. 18 years of age or older
   
   b. Improvement in symptoms

   AND ALL of the following for BOTH indications:
   
   1. NOT used for the relief of acute bronchospasm or status asthmaticus
   
   2. NO dual therapy with another monoclonal antibody for the treatment of asthma

All approved requests are subject to review by a clinical specialist for final validation and coverage determination once all required documentation has been received. Current utilization, including samples, does not guarantee approval of coverage.

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity

<table>
<thead>
<tr>
<th>Drug/Strength</th>
<th>Indication</th>
<th>Quantity per days supply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasenra 30 mg</td>
<td>Severe asthma</td>
<td>5 single dose syringes per 180 days OR</td>
</tr>
<tr>
<td>Nucala 100 mg</td>
<td>EGPA</td>
<td>9 injections per 90 days OR</td>
</tr>
<tr>
<td>Nucala 100 mg*</td>
<td>Severe asthma</td>
<td>3 injections per 90 days</td>
</tr>
<tr>
<td></td>
<td>*Ages 6-11 approved for vial formulation ONLY</td>
<td></td>
</tr>
</tbody>
</table>

Duration

6 months

Prior – Approval Renewal Limits

Quantity

<table>
<thead>
<tr>
<th>Drug/Strength</th>
<th>Indication</th>
<th>Quantity per days supply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasenra 30 mg</td>
<td>Severe asthma</td>
<td>3 single dose syringes per 180 days OR</td>
</tr>
<tr>
<td>Nucala 100 mg</td>
<td>EGPA</td>
<td>9 injections per 90 days OR</td>
</tr>
<tr>
<td>Nucala 100 mg*</td>
<td>Severe asthma</td>
<td>3 injections per 90 days</td>
</tr>
</tbody>
</table>
**Rationale**

**Summary**

Fasenra and Nucala are used with other asthma medications for the maintenance treatment of asthma in patients with an eosinophilic phenotype. Fasenra and Nucala have been shown to decrease the incidence of asthma exacerbations in patients with severe asthma whose symptoms are inadequately controlled with inhaled corticosteroids. Nucala is also used in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). Fasenra and Nucala are not indicated for the relief of acute bronchospasm or status asthmaticus (1-2).

Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Fasenra and Nucala while maintaining optimal therapeutic outcomes.

**References**


**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>December 2015</td>
<td>Addition to PA</td>
</tr>
<tr>
<td>March 2016</td>
<td>Annual editorial review</td>
</tr>
<tr>
<td></td>
<td>Addition of the requirement of the patient must have one of the following:</td>
</tr>
<tr>
<td></td>
<td>eosinophil count greater than or equal 150 cells/mCL in the past 90 days, or</td>
</tr>
<tr>
<td></td>
<td>eosinophil count greater than or equal 300 cells/mCL in the past 12 months</td>
</tr>
<tr>
<td></td>
<td>also, varicella vaccination has been given prior to Nucala therapy per SME</td>
</tr>
<tr>
<td></td>
<td>Policy number change from 5.13.07</td>
</tr>
<tr>
<td>June 2016</td>
<td>Annual review</td>
</tr>
<tr>
<td>September 2016</td>
<td>Clarified dual therapy statement and addition of age to renewal</td>
</tr>
<tr>
<td></td>
<td>Change of the varicella vaccination requirement to Prescriber will assess the medical appropriateness for a varicella vaccination prior to therapy</td>
</tr>
<tr>
<td>March 2017</td>
<td>Annual editorial review</td>
</tr>
<tr>
<td>December 2017</td>
<td>Addition of Fasenra and quantity limits on both medications</td>
</tr>
</tbody>
</table>

*Ages 6-11 approved for vial formulation ONLY*
January 2018  Addition of new indication for Nucala eosinophilic granulomatosis with polyangiitis (EGPA). Removal of the requirement for other eosinophilic conditions
March 2018  Annual review
June 2018  Annual editorial review
            Addition of requirement for asthma: Inadequate control of asthmatic symptoms after a minimum of 3 months of ONE of the following: Inhaled corticosteroids & long acting beta\textsubscript{2} agonist or Inhaled corticosteroids & long acting muscarinic antagonist
November 2018  Change of Nucala eosinophil count requirement from > 1500 cells/mcL to > 1000 cells/mcL
March 2019  Annual review
August 2019  Addition of the 50% adherence requirement to the asthma diagnosis. Removed requirement to use in combination with ICS + LABA and addition of renewal requirement to be compliant on therapy. Addition to managed PA program
September 2019  Annual review and reference update. Decreased Nucala age limit for severe asthma to 6 and older from 12 and older and added requirement to dose within FDA labeled maintenance dose for patients age 6-11 for Nucala

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on September 13, 2019 and is effective on October 1, 2019.